and NO has emerged as an important intra and/or intercellular messenger involved in the control of the hypothalamic-pituitary axis (11) (12) (13) (14) and in the NMDA actions on LHRH/LH release (15, 16) .
Prolactin release is controlled by multiple hypothalamic and peripheral signals. Dopamine is the principal central inhibitory signal (1) , while serotonin, vasoactive intestinal polypeptide, TRH and other neuropeptides increased PRL release (2, 3) . Recently it has been shown that systemic administration of N-methyl-o-aspartic acid (NMDA), an agonist of NMDA receptors, to adult male rats increases the secretion of PRL (4) (5) (6) . The stimulatory effect of NMDA on PRL secretion may involve an increase in the secretion of PRL-releasing factors (PRFs), a decrease in dopamine release or a direct action on lactotrophs (6, 7) . However, under certain circumstances, NMDA inhibits PRL release (8) (9) (10) and antagonization of NMDA receptors results in increase in PRL secretion (7) . Furthermore, kainic acid (KA) systemically given inhibits PRL secretion in males (10) and lactating female rats (8) .
By using immunohistochemistry and hybridation in situ, the presence of nitric oxide (NO) synthase have been located in hypothalamic areas and pituitary cells (11, 12) and NO has emerged as an important intra and/or intercellular messenger involved in the control of the hypothalamic-pituitary axis (11) (12) (13) (14) and in the NMDA actions on LHRH/LH release (15, 16) .
The following experiments were performed in pre¬ pubertà! female rats to analyse: the control of PRL secretion by NMDA (Table 1) .
N-Methyl-D-aspartate injected at doses of 15 and 40 mg/kg reduced significantly and to a similar extent the serum PRL concentrations. Also, a significant decrease in PRL levels was observed after NAME administration. The effects of NAME and NMDA were not additive because the observed reduction of PRL was similar after injection of one or both drugs (Fig. 3) . The dopamine concentrations were increased in the pituitary and decreased in the hypothalamus after administration of NMDA, NAME or NMDA plus NAME (Fig. 4) , whereas the pituitary 5-HT concen¬ trations remained unchanged after all treatments (Fig. 5) .
The reduced PRL secretion observed 15 the inhibitory effect of KA was blocked by NAME and by NA (Fig. 6 ).
The inhibitory effect of NMDA, KA and NAME on PRL secretion seems to be age-dependent, because NMDA stimulated PRL secretion in adult females, but KA and NAME were ineffective ( (4) (5) (6) , but the effect of NMDA changes both quantita¬ tively and qualitatively, depending on the endocrine state. Inhibitory effects of NMDA and KA were observed in lactating females (8, 9) and in normo-and hyperprolactinaemic males (10) . Furthermore (22) , and through a direct action on lactotrophs (7) . The 3.76 ± 0.38 ng/ml, respectively), and the stimulating effect of A on LH secretion was not modified by NAME (26) . Considering that NO generation in the central nervous system is increased by NMDA and KA (27, 28) and decreased by NAME, the increase in DA release after administration of NMDA, KA 
